Corporate News

Block Listing Six Monthly Return

27 July 2023

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced MRI scanning of the lungs, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:		Polarean Imaging Plc
Name of scheme:		Polarean Share Option Plan
Number and class of securities originally admitted:		8,000,000 ordinary shares of £0.00037 each
Date of admission:		29 July 2021
Period of return:	From:	26 January 2023	To:	26 July 2023
Balance of unallotted securities under scheme(s) from previous return:		4,025,657
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		852,822
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		3,172,835
Total number of securities in issue at the end of the period		213,900,331

Name of contact:	Charles F. Osborne, Jr., Chief Financial Officer
Telephone number of contact:	+ 44 (0)20 7933 8780 or [email protected]

Enquiries:

Polarean Imaging plc			www.polarean.com / www.polarean-ir.com
Christopher von Jako, Chief Executive Officer			Via Walbrook PR
Kenneth West, Chairman

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)				+44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)
Nick Adams / Nick Harland (Corporate Broking)

Walbrook PR	Tel: +44 (0)20 7933 8780 or [email protected]
Anna Dunphy /Phillip Marriage		Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the “Group”) are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterise disease progression, and monitor response to treatment. By researching, developing, and commercialising novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean’s vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States. The company also commercialises systems (such as the HPX hyperpolarisation system), accessories (such as Xe-specific chest coils and phantoms) and FDA-cleared post-processing software (to support ventilation defect analysis), to support fully integrated modern respiratory imaging operations.

PLC-RNS-2314

« back to Corporate News